CMS May Take Lead In Federal Compounding Oversight After Court Ruling
Executive Summary
The Centers for Medicare & Medicaid Services may serve as a stronger regulatory presence for pharmacy compounders in light of a recent federal court decision rejecting FDA's enforcement authority over the practice
You may also be interested in...
Wyeth Loses Citizen Petition Battle But Wins War Over Compounded Hormones
Wyeth will probably be satisfied by FDA's response to its citizen petition appealing for regulatory action against pharmacies distributing compounded hormone replacement therapy products. Although the agency denied the bulk of Wyeth's petition, FDA took action against compounding pharmacies for several related violations
Wyeth Loses Citizen Petition Battle But Wins War Over Compounded Hormones
Wyeth will probably be satisfied by FDA's response to its citizen petition appealing for regulatory action against pharmacies distributing compounded hormone replacement therapy products. Although the agency denied the bulk of Wyeth's petition, FDA took action against compounding pharmacies for several related violations
Avastin Widespread Availability For Eye Use May Depend On FDA Clearance
FDA has taken center stage in the skirmish over Avastin's off-label use in patients with age-related macular degeneration